WORLD’S CLINICAL LABORATORY NEWS LEADER ISSN 1068-1760
Vol. 39 No.5 • 8-9/2022
V I S I T
DAILY CLINICAL LAB NEWS
®
I
N
T
E
First-Ever Blood Test For Parkinson’s Disease ntil now, the diagnosis of Parkinson’s disease has been based primarily on typical movement disorders such as muscle stiffness, slower movements and shaking. However, the disease starts up to 20 years before it becomes noticeable as a result
U
R
N
A
T
I
O
N
Diseases Diagnosed by Isolating Biomarkers in Tears urrent clinical studies pose significant challenges in distinguishing disease subtypes with accurate molecular signatures and tracking the disease progression in a non-invasive way. Identifying molecular clues in samples from patients, such as specific proteins
C
or genes from vesicular structures called exosomes, could improve the accuracy of diagnoses. Since small extracellular vesicles (sEVs, exosomes) reveal specific functions in various biological processes, including immune regulation, angiogenesis, tumor
Cont’d on page 20
Cont’d on page 13
International Meetings Rebound After Long COVID Hiatus
A
L
Blood Test Can Aid Cancer Treatment etastatic cancer – cancer that has spread to other organs in the body – is not often curable, and chemotherapy and newer targeted therapies may not work for all patients. Biopsies to help determine the best treatments for this type of cancer are rarely performed due to their invasive nature and the high risk of complications. This is often a major barrier in studying and
M
Cont’d on page 14
Maternal Autoantibodies As Autism Biomarkers
fter showing first signs of life with EuroMedLab in Munich (April 1014) and WorldLab in Seoul (June 26-30), international meetings returned in full force with AACC 2022 held in Chicago on July 24-28. LabMedica’s roundup of latest advances unveiled at the event starts on Page 7.
A
utism is a neurodevelopment condition affecting 1 in 44 children in the U.S. It has a wide range of characteristics with different intensities and causes. One type of autism is maternal autoantibody–related autism spectrum disorder (MAR ASD). MAR ASD is marked by the presence of specific maternal immune proteins known as autoantibodies that react to certain
A
Cont’d on page 18 V
I
S
I
T
LINKXPRESS COM R E A D E R
S E R V I C E
®
P O R T A L
Renew/Start your Free Subscription Access Interactive Digital Magazine Instant Online Product Information: Identify LinkXpress codes of 1 interest as you read magazine ®
on LinkXpress.com 2 toClick reach reader service portal
3
Mark code(s) of interest on LinkXpress ® inquiry matrix
If your subscription is not renewed every 12 months your Free Subscription may be automatically discontinued
Women’s POCT Platform Wins 2022 AACC Award
INSIDE
his year’s prestigious “AACC Disruptive Technology Award” went to Nanopath Inc., for the company’s point-of-care testing (POCT) platform for women’s health, based on breakthrough molecular diagnostics technology that can provide results in minutes instead of days.
COVID-19 Update. . . . . 4
T
Cont’d on page 6
Growth of Point-of-Care Testing Driven By Molecular Diagnostics Advances he global point-of-care (POC) testing market is projected to reach USD 70.8 billion by 2030, driven by an increasing number of pathology labs and services equipped with advanced diagnostic equipment. Molecular testing technology allows nucleic
T
acid detection directly through amplification and screening of sample. As a result, industry players have been focusing their efforts on developing new POC molecular diagnostic technologies to deliver faster results with high accuracy and specificity. Cont’d on page 17
AACC 2022 Roundup. . 7 Clinical News. . . . . . . . 13 IFCC News. . . . . . . . . . 21 Product News . . . . . 6-20 Events Calendar . . . . . 26 PUBLISHED IN COOPERATION WITH
International Federation of Clinical Chemistry and Laboratory Medicine
GLOBETECH >>> MEDIA <<<